about
Padma 28 for intermittent claudicationRutosides for prevention of post-thrombotic syndromeRutosides for treatment of post-thrombotic syndromeγ-Glutamyltransferase, but not markers of hepatic fibrosis, is associated with cardiovascular disease in older people with type 2 diabetes mellitus: the Edinburgh Type 2 Diabetes StudySystematic review with meta-analysis: vasoactive drugs for the treatment of hepatorenal syndrome type 1.Socioeconomic deprivation increases the effect of winter on admissions to hospital with COPD: retrospective analysis of 10 years of national hospitalisation data.Cardiovascular risk factors and cognitive decline in older people with type 2 diabetes.Clinically significant chronic liver disease in people with Type 2 diabetes: the Edinburgh Type 2 Diabetes Study.Clinical and subclinical macrovascular disease as predictors of cognitive decline in older patients with type 2 diabetes: the Edinburgh Type 2 Diabetes Study.Commissioning prison health: opportunities and challenges for creating a new prison public health system in Scotland.Is there a divergence in time trends in the prevalence of impaired glucose tolerance and diabetes? A systematic review in South Asian populations.Using non-invasive biomarkers to identify hepatic fibrosis in people with type 2 diabetes mellitus: the Edinburgh type 2 diabetes study.Adverse events after first, single, mesh and non-mesh surgical procedures for stress urinary incontinence and pelvic organ prolapse in Scotland, 1997-2016: a population-based cohort study.Type 2 diabetes and risk of hospital admission or death for chronic liver diseases.Association Between Psychological Distress and Liver Disease Mortality: A Meta-analysis of Individual Study Participants.Hepatic steatosis and non-alcoholic fatty liver disease are not associated with decline in renal function in people with Type 2 diabetes.Non-invasive hepatic biomarkers (ELF and CK18) in people with type 2 diabetes: the Edinburgh type 2 diabetes study.Severe hypoglycemia and cognitive decline in older people with type 2 diabetes: the Edinburgh type 2 diabetes study.Cardiovascular Disease, Cancer, and Mortality Among People With Type 2 Diabetes and Alcoholic or Nonalcoholic Fatty Liver Disease Hospital Admission.Could stool collection devices help increase uptake in bowel cancer screening programmes?N-terminal pro-brain natriuretic peptide and risk of cardiovascular events in older patients with type 2 diabetes: the Edinburgh Type 2 Diabetes Study.Completeness of primary intracranial tumour recording in the Scottish Cancer Registry 2011-2012.Enhanced detection services for developmental dysplasia of the hip in Scottish children, 1997-2013.Attitudes to shared care for patients with dementia: a survey of general practitioners.Rutosides for treatment of post-thrombotic syndromeRutosides for prevention of post-thrombotic syndromeGathering momentum for the way ahead: fifth report of the Lancet Standing Commission on Liver Disease in the UKPrevalence of abnormal plasma liver enzymes in older people with Type 2 diabetesLet's talkBiomarkers of liver fibrosisAssociation Between Severe Hypoglycemia, Adverse Macrovascular Events, and Inflammation in the Edinburgh Type 2 Diabetes StudyUnacceptable failures: the final report of the Lancet Commission into liver disease in the UKPrevention: of what, in whom, and how?Editorial: how widespread and serious is non-alcoholic fatty liver disease in the real world?
P50
Q24186000-3FAA2D00-E815-4D86-8F20-289156BCC88AQ24187151-ADFFA46C-BDDA-4880-90AF-9C7521D01C39Q24187159-1006FB50-DC92-4DC0-94FE-3AB5AF6B242DQ28648219-A1C5CA7F-FE47-46CC-990A-6B677AF642B1Q30239846-FD6BE9A9-4ADB-45FB-803A-05B0318B4D85Q30652776-5FFC1505-E158-40F5-9A7E-DDD512D1F3B1Q35757186-671B963F-1EB0-44CE-8DDE-0370BBBC1EF8Q36750183-EBE4211B-8BF0-4555-AD6F-6F5692EC7DD9Q37106524-766D2FDA-A48D-4CE3-916D-15A07EE39795Q37524933-D63C8B90-7BFD-4E55-99EA-C8049DED5925Q37967126-C0A4FFAF-F3B0-4B72-BF33-690606790138Q39253135-65321393-48E9-4377-B5EB-C7EFFB5A61EDQ40409872-5D8E95C7-8FD9-49AE-9887-96D0507DFA94Q40950269-138BFC58-7DD5-4B50-A868-A1D9F3ADBA1BQ41438177-063BB8C1-9891-48FE-BEE5-C85DEF439804Q44682506-CB79ABFB-7682-4A25-B0DB-95A63D5DC02AQ45402850-E5AE65DC-314E-4EA4-B4A3-294BE15691C9Q46944759-6310C931-8D87-40DA-ACFC-0E9302818E5FQ47426610-0D4ADB22-918B-4CA9-B019-512651588E44Q48104229-AF2054BD-7F25-450E-9195-CFC272DF5534Q48535643-6178AA04-252B-4EF0-ADE7-CD64B5691EF8Q48644034-83F56838-3BBA-45B8-9C5A-3CA4AAEF6D71Q50048591-280AA76B-FDE6-445E-90FF-B34DAEB4A3DBQ54441620-76C51B69-8802-496B-BD33-8E5EF7ED2A1FQ58578352-7A26DCA6-DFE7-44FD-9796-D7D9047CF172Q58578357-EF453C3D-7EDA-4CD5-8D08-2DB70D89B3DAQ59350127-64FBFFDE-4488-485E-84EA-AF2E6A149ECEQ61415545-3426CCE7-722B-4825-9935-279F6366767CQ62626254-60E9E060-23D7-4C8C-AC44-15D2B3B9691DQ62626273-811A2E61-043B-4FF9-90DC-E95389BF8950Q62626311-C6FFD9C1-9F42-4A4C-AB5C-88A60A7C0F2BQ91615019-E6C14993-F684-4FB2-B6A7-F7BA7959ED60Q93062349-B874EE59-9890-43D2-ADA3-733C40FDD689Q95337681-B66B7416-613C-4A78-A4C2-311F33CC4662
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Joanne R. Morling
@ast
Joanne R. Morling
@en
Joanne R. Morling
@es
Joanne R. Morling
@sl
type
label
Joanne R. Morling
@ast
Joanne R. Morling
@en
Joanne R. Morling
@es
Joanne R. Morling
@sl
altLabel
Jo Morling
@en
prefLabel
Joanne R. Morling
@ast
Joanne R. Morling
@en
Joanne R. Morling
@es
Joanne R. Morling
@sl
P106
P1153
26650061900
P21
P31
P496
0000-0003-0772-2893